The treatment strategy for ALK-positive Non-small-cell Lung Carcinoma

Abstract

ALK-positive lung cancer accounts for approximately 4% of all lung cancer. Tyrosine kinase inhibitors targeting the ALK domain (ALK-TKI) are being rapidly developed. We can use crizotinib as a 1st generation ALK-TKI, and alectinib and ceritinib as 2nd generation ALK-TKIs. Third generation ALK-TKIs (lorlatinib and brigatinib) are also expected to have therapeutic effects. We mainly discuss these ALK-TKIs based on the results of study, and we explain the position of ALK-TKIs in the practice guidelines for lung cancer, as well as the methods for choosing the 1st and 2nd line drugs.